Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Abstract

Ceftazidime-avibactam and ceftolozane-tazobactam are currently FDA-approved and available for use, while cefiderocol and imipenem-cilastatin/relebactam are in development. Current evidence suggests ceftazidime-avibactam and ceftolozane-tazobactam both may have a role in treatment of MDR P. aeruginosa infections. Ceftolozane-tazobactam appears to be modestly more potent against P. aeruginosa, but emergence of resistance has been noted in various reported cases. Trials are ongoing for cefiderocol and imipenem-cilastatin/relebactam and early results appear promising. The aforementioned agents fill important gaps in the antibiotic armamentarium, particularly for patients with MDR P. aeruginosa infections who otherwise have extremely limited and often toxic antibiotic options. However, resistance to all of these agents will likely emerge, and additional antibiotic development is warranted to provide sufficient options to successfully manage MDR P. aeruginosa infections.

Three Year Resistance Profile of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> Strains Isolated from Intensive Care Units

“…(13,14). Acinetobacter baumannii ve Pseudomonas aeruginosa'da yıllar içerisinde dikkat çeken bir antibiyotik direnç artışı ve çoğul direnç mevcuttur (15,16). Dünya Sağlık Örgütü'nün (DSÖ) Şubat 2017'de yayınladığı yeni antibiyotiklere acilen ihtiyaç duyulan öncelikli patojenler listesinde Acinetobacter baumannii ve Pseudomonas aeruginosa öncelik 1 (kritik) grubunda yer almaktadır (17).…”

Thiostrepton Hijacks Pyoverdine Receptors To Inhibit Growth of Pseudomonas aeruginosa

“…It is intrinsically resistant to many antibiotics and forms biofilms, further enhancing its ability to evade therapy (7). The low permeability of its outer membrane and expression of multiple efflux pumps that extrude a wide variety of substrates, coupled with its propensity to form biofilms, limit the repertoire of effective anti-Pseudomonas antibiotics (8)(9)(10). Here, with the aim of identifying potential modulators of P. aeruginosa biofilm formation, we screened a collection of bioactive molecules, including previously FDA-approved offpatent drugs, at 10 M. During this work, we identified 60 growth inhibitors, plus an additional 60 molecules that stimulated biofilm formation beyond our arbitrary cutoff of 200% of the vehicle control, a phenotype associated with exposure to sub-MIC antibiotics (11,12).…”

Homalomena pineodora essential oil nanoparticle inhibits diabetic wound pathogens

“…The MLC results were significantly higher than MIC results aa higher EoNP concentration A grade 1B ulcer was classified as an infected superficial wound that does not include tendon, capsule or bone 28 . This model utilised type I collagen because this type of collagen is most abundant in the dermis 29 . Following the biofilm formation, the presence of type I collagen also was identified as an effective substrate for bacterial attachment 30 .…”